|By Marketwired .||
|June 12, 2014 11:27 AM EDT||
NEW YORK, NY -- (Marketwired) -- 06/12/14 -- A review of more than 20 years of prostate cancer data revealed that a man's age at the time of his diagnosis is a significant predictor of his long-term cancer-specific mortality (CSM) odds. Using Surveillance Epidemiology and End Results (SEER) data from 1988 to 2009, researchers evaluated the CSM and other-cause mortality (OCM) of localized prostate cancer patients.
Researchers reviewed prostate cancer diagnosis and mortality data from more than 205,000 men, all of whom were treated with radical prostatectomy. According to David Samadi, MD, Chairman of Urology and Chief of Robotic Surgery at Lenox Hill Hospital, several key findings emerged. "Radical prostatectomy success is not age-specific. As this study reminds, prostate cancer treatment decisions require expert counsel in disease status, overall health, and treatment outcomes."
Key prostate cancer diagnosis findings
Age affects outcomes: Prostate cancer diagnosis over age 70 was associated with the highest risk of CSM at 15 years post-diagnosis. The lowest risk was see in men age 50 years or younger at the time of diagnosis.
Age isn't everything: Gleason score and tumor status at diagnosis may trump age. For men diagnosed with aggressive prostate, age was not the only factor in prostate cancer-related 15-year mortality.
Prostate cancer diagnosis age is dropping: From 1988 to 2009 the median age of diagnosis fell from 66 years to 61 years. The number of men diagnosed under the age of 50 increased 6 percent over the course of the study.
"I'm very happy to see the diagnosis age dropping," said Dr. Samadi. "These men are most likely adhering to routine screening and PSA testing. When we catch the disease in its early stages, we improve our odds for successful, definitive treatment like robotic prostate surgery."
The study findings were published in The Journal of Urology, April 2014, http://www.jurology.com/article/S0022-5347%2814%2901234-8/fulltext.
David B. Samadi, MD, has performed more than 5,600 successful robotic prostate removal surgeries to date. His innovative technique -- the Samadi Modified Advanced Robotic Technique (SMART) Surgery -- yields superior post-surgery quality of life results in urinary continence, sexual potency, and patient satisfaction.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2616378
David B. Samadi, M.D
Chairman of Urology
Chief of Robotic Surgery at Lenox Hill Hospital
485 Madison Avenue
New York, NY 10022